Cargando…

Different pH-sensitivity patterns of 30 sodium channel inhibitors suggest chemically different pools along the access pathway

The major drug binding site of sodium channels is inaccessible from the extracellular side, drug molecules can only access it either from the membrane phase, or from the intracellular aqueous phase. For this reason, ligand-membrane interactions are as important determinants of inhibitor properties,...

Descripción completa

Detalles Bibliográficos
Autores principales: Lazar, Alexandra, Lenkey, Nora, Pesti, Krisztina, Fodor, Laszlo, Mike, Arpad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4585259/
https://www.ncbi.nlm.nih.gov/pubmed/26441665
http://dx.doi.org/10.3389/fphar.2015.00210
_version_ 1782392167385268224
author Lazar, Alexandra
Lenkey, Nora
Pesti, Krisztina
Fodor, Laszlo
Mike, Arpad
author_facet Lazar, Alexandra
Lenkey, Nora
Pesti, Krisztina
Fodor, Laszlo
Mike, Arpad
author_sort Lazar, Alexandra
collection PubMed
description The major drug binding site of sodium channels is inaccessible from the extracellular side, drug molecules can only access it either from the membrane phase, or from the intracellular aqueous phase. For this reason, ligand-membrane interactions are as important determinants of inhibitor properties, as ligand-protein interactions. One-way to probe this is to modify the pH of the extracellular fluid, which alters the ratio of charged vs. uncharged forms of some compounds, thereby changing their interaction with the membrane. In this electrophysiology study we used three different pH values: 6.0, 7.3, and 8.6 to test the significance of the protonation-deprotonation equilibrium in drug access and affinity. We investigated drugs of several different indications: carbamazepine, lamotrigine, phenytoin, lidocaine, bupivacaine, mexiletine, flecainide, ranolazine, riluzole, memantine, ritanserin, tolperisone, silperisone, ambroxol, haloperidol, chlorpromazine, clozapine, fluoxetine, sertraline, paroxetine, amitriptyline, imipramine, desipramine, maprotiline, nisoxetine, mianserin, mirtazapine, venlafaxine, nefazodone, and trazodone. We recorded the pH-dependence of potency, reversibility, as well as onset/offset kinetics. As expected, we observed a strong correlation between the acidic dissociation constant (pKa) of drugs and the pH-dependence of their potency. Unexpectedly, however, the pH-dependence of reversibility or kinetics showed diverse patterns, not simple correlation. Our data are best explained by a model where drug molecules can be trapped in at least two chemically different environments: A hydrophilic trap (which may be the aqueous cavity within the inner vestibule), which favors polar and less lipophilic compounds, and a lipophilic trap (which may be the membrane phase itself, and/or lipophilic binding sites on the channel). Rescue from the hydrophilic and lipophilic traps can be promoted by alkalic and acidic extracellular pH, respectively.
format Online
Article
Text
id pubmed-4585259
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-45852592015-10-05 Different pH-sensitivity patterns of 30 sodium channel inhibitors suggest chemically different pools along the access pathway Lazar, Alexandra Lenkey, Nora Pesti, Krisztina Fodor, Laszlo Mike, Arpad Front Pharmacol Pharmacology The major drug binding site of sodium channels is inaccessible from the extracellular side, drug molecules can only access it either from the membrane phase, or from the intracellular aqueous phase. For this reason, ligand-membrane interactions are as important determinants of inhibitor properties, as ligand-protein interactions. One-way to probe this is to modify the pH of the extracellular fluid, which alters the ratio of charged vs. uncharged forms of some compounds, thereby changing their interaction with the membrane. In this electrophysiology study we used three different pH values: 6.0, 7.3, and 8.6 to test the significance of the protonation-deprotonation equilibrium in drug access and affinity. We investigated drugs of several different indications: carbamazepine, lamotrigine, phenytoin, lidocaine, bupivacaine, mexiletine, flecainide, ranolazine, riluzole, memantine, ritanserin, tolperisone, silperisone, ambroxol, haloperidol, chlorpromazine, clozapine, fluoxetine, sertraline, paroxetine, amitriptyline, imipramine, desipramine, maprotiline, nisoxetine, mianserin, mirtazapine, venlafaxine, nefazodone, and trazodone. We recorded the pH-dependence of potency, reversibility, as well as onset/offset kinetics. As expected, we observed a strong correlation between the acidic dissociation constant (pKa) of drugs and the pH-dependence of their potency. Unexpectedly, however, the pH-dependence of reversibility or kinetics showed diverse patterns, not simple correlation. Our data are best explained by a model where drug molecules can be trapped in at least two chemically different environments: A hydrophilic trap (which may be the aqueous cavity within the inner vestibule), which favors polar and less lipophilic compounds, and a lipophilic trap (which may be the membrane phase itself, and/or lipophilic binding sites on the channel). Rescue from the hydrophilic and lipophilic traps can be promoted by alkalic and acidic extracellular pH, respectively. Frontiers Media S.A. 2015-09-25 /pmc/articles/PMC4585259/ /pubmed/26441665 http://dx.doi.org/10.3389/fphar.2015.00210 Text en Copyright © 2015 Lazar, Lenkey, Pesti, Fodor and Mike. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Lazar, Alexandra
Lenkey, Nora
Pesti, Krisztina
Fodor, Laszlo
Mike, Arpad
Different pH-sensitivity patterns of 30 sodium channel inhibitors suggest chemically different pools along the access pathway
title Different pH-sensitivity patterns of 30 sodium channel inhibitors suggest chemically different pools along the access pathway
title_full Different pH-sensitivity patterns of 30 sodium channel inhibitors suggest chemically different pools along the access pathway
title_fullStr Different pH-sensitivity patterns of 30 sodium channel inhibitors suggest chemically different pools along the access pathway
title_full_unstemmed Different pH-sensitivity patterns of 30 sodium channel inhibitors suggest chemically different pools along the access pathway
title_short Different pH-sensitivity patterns of 30 sodium channel inhibitors suggest chemically different pools along the access pathway
title_sort different ph-sensitivity patterns of 30 sodium channel inhibitors suggest chemically different pools along the access pathway
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4585259/
https://www.ncbi.nlm.nih.gov/pubmed/26441665
http://dx.doi.org/10.3389/fphar.2015.00210
work_keys_str_mv AT lazaralexandra differentphsensitivitypatternsof30sodiumchannelinhibitorssuggestchemicallydifferentpoolsalongtheaccesspathway
AT lenkeynora differentphsensitivitypatternsof30sodiumchannelinhibitorssuggestchemicallydifferentpoolsalongtheaccesspathway
AT pestikrisztina differentphsensitivitypatternsof30sodiumchannelinhibitorssuggestchemicallydifferentpoolsalongtheaccesspathway
AT fodorlaszlo differentphsensitivitypatternsof30sodiumchannelinhibitorssuggestchemicallydifferentpoolsalongtheaccesspathway
AT mikearpad differentphsensitivitypatternsof30sodiumchannelinhibitorssuggestchemicallydifferentpoolsalongtheaccesspathway